Further studies are in progress to understand whether, as already shown in CRC and NSCLC models, p65BTK expression levels correlate with RAS/MAPK dysregulation and whether BTK inhibitors are synergic with other targeted therapy, such as EGFR inhibitors, or SOC therapy. This evidence concerns the gene EGFR and colorectal carcinoma.